Sedation - Pipeline Review, H2 2018

Publisher Name :
Date: 10-Jul-2018
No. of pages: 55
Inquire Before Buying

Sedation - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sedation - Pipeline Review, H2 2018, provides an overview of the Sedation (Central Nervous System) pipeline landscape.

Sedation is the depression of irritability or agitation. Symptoms include talk slowly and may slur their speech, unable to concentrate, feel dizzy, slow breathing, heart rate, blood pressure will be lower. Treatment includes barbiturates and benzodiazepines.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sedation - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Sedation (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sedation (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Sedation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III and Preclinical stages are 1, 4 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Sedation (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Sedation (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Sedation (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Sedation (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Sedation (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Sedation (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Sedation (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Sedation (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Sedation - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Sedation - Overview
Sedation - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Sedation - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Sedation - Companies Involved in Therapeutics Development
Drawbridge Pharmaceuticals Pty Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Nhwa Pharmaceutical Corp Ltd
Paion AG
Primex Pharmaceuticals Oy
Therakind Ltd
Sedation - Drug Profiles
alphaxalone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
clonidine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EL-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HR-7056 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
midazolam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
propofol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remimazolam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SERx-480 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GABA-A for Sedation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XK-568b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sedation - Dormant Projects
Sedation - Discontinued Products
Sedation - Product Development Milestones
Featured News & Press Releases
Jun 01, 2018: Primex Pharmaceuticals presents ADV6209 at Euroanesthesia 2018
Nov 14, 2017: FDA Considers Current Human Abuse Liability Program with Remimazolam in the U.S. As Sufficient; no Second Intranasal Study Required
Sep 28, 2017: European Patent Office Grants Formulation Patent For Remimazolam In The EU
Jun 05, 2017: Primex Pharmaceuticals at Euroanesthesia 2017: Next Innovation in the Management of Pediatric Sedation
Oct 19, 2016: Positive Remimazolam Phase III Colonoscopy Results Presented at the 2016 American College of Gastroenterology Annual Scientific Meeting
Oct 05, 2016: Primex Files for Marketing Authorization for a pediatrics sedative medication
Sep 22, 2016: PAION: Remimazolam Phase III Colonoscopy Data to Be Presented at the American College of Gastroenterology 2016 Meeting
Sep 06, 2016: PAION announces clinical development progress with remimazolam by its Partner Yichang Humanwell in China
Sep 01, 2016: Primex Announces Phase II Results of ADV6209 at the 16th World Congress of Anesthesiologists
Aug 31, 2016: Primex Pharmaceuticals: Next real innovation in pediatric anesthesia since propofol
Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy
Apr 11, 2016: Paion Successfully Completes Patient Recruitment In Phase III Study With Remimazolam For Procedural Sedation During Colonoscopy
Feb 12, 2016: Paion: US-Patent & Trademark Office Grants Substance Patent For Remimazolam Besylate
Feb 09, 2016: Paion Discontinues European Remimazolam Phase III Trial In Cardiac Surgery Patients Due To Insufficient Recruitment
Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Sedation, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Sedation - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H2 2018
Sedation - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2018
Sedation - Pipeline by Jiangsu Nhwa Pharmaceutical Corp Ltd, H2 2018
Sedation - Pipeline by Paion AG, H2 2018
Sedation - Pipeline by Primex Pharmaceuticals Oy, H2 2018
Sedation - Pipeline by Therakind Ltd, H2 2018
Sedation - Dormant Projects, H2 2018
Sedation - Discontinued Products, H2 2018

List of Figures
Number of Products under Development for Sedation, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018
  • Anesthetic Effect - Pipeline Review, H2 2018
    Published: 30-Oct-2018        Price: US 2000 Onwards        Pages: 82
    Anesthetic Effect - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anesthetic Effect - Pipeline Review, H2 2018, provides an overview of the Anesthetic Effect (Central Nervous System) pipeline landscape. Anesthetic effect causes a loss of consciousness. The factors that can increase risk of complications include smoking, obstructive sleep apnea, obesity, high blood pressure, history of ad......
  • Schizophrenia - Pipeline Review, H2 2018
    Published: 30-Oct-2018        Price: US 2000 Onwards        Pages: 321
    Schizophrenia - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Schizophrenia - Pipeline Review, H2 2018, provides an overview of the Schizophrenia (Central Nervous System) pipeline landscape. Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and dis......
  • Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2018
    Published: 30-Oct-2018        Price: US 2000 Onwards        Pages: 551
    Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2018, provides an overview of the Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline landscape. Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. The disorder is named for its underlying pathop......
  • Insomnia - Pipeline Review, H2 2018
    Published: 09-Oct-2018        Price: US 2000 Onwards        Pages: 116
    Insomnia - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Insomnia - Pipeline Review, H2 2018, provides an overview of the Insomnia (Central Nervous System) pipeline landscape. Insomnia is a sleep disorder that is characterized by difficulty falling and/or staying asleep. Symptoms include difficulty falling asleep at night, irritability, depression or anxiety, tension headaches and distre......
  • Narcolepsy - Pipeline Review, H2 2018
    Published: 09-Oct-2018        Price: US 2000 Onwards        Pages: 88
    Narcolepsy - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy - Pipeline Review, H2 2018, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape. Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations and sleep paral......
  • Spinal Cord Injury - Pipeline Review, H2 2018
    Published: 09-Oct-2018        Price: US 2000 Onwards        Pages: 199
    Spinal Cord Injury - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Cord Injury - Pipeline Review, H2 2018, provides an overview of the Spinal Cord Injury (Central Nervous System) pipeline landscape. Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually cau......
  • Guillain-Barre Syndrome - Pipeline Review, H2 2018
    Published: 09-Oct-2018        Price: US 2000 Onwards        Pages: 51
    Guillain-Barre Syndrome - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Guillain-Barre Syndrome - Pipeline Review, H2 2018, provides an overview of the Guillain-Barre Syndrome (Central Nervous System) pipeline landscape. Guillain-Barre syndrome (GBS) is a disorder in which the body's immune system attacks part of the peripheral nervous system. The first symptoms of this disorder include ......
  • Low Back Pain - Pipeline Review, H2 2018
    Published: 09-Oct-2018        Price: US 2000 Onwards        Pages: 113
    Low Back Pain - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Low Back Pain - Pipeline Review, H2 2018, provides an overview of the Low Back Pain (Central Nervous System) pipeline landscape. Low back pain can happen anywhere below the ribs and above the legs. Causes of low back pain include overuse, strain, or injury, aging, arthritis, illness and cancer involving the spine. Symptoms inc......
  • Binge Eating Disorder - Pipeline Review, H2 2018
    Published: 09-Oct-2018        Price: US 2000 Onwards        Pages: 50
    Binge Eating Disorder - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Binge Eating Disorder - Pipeline Review, H2 2018, provides an overview of the Binge Eating Disorder (Central Nervous System) pipeline landscape. Binge eating disorder is a serious condition characterized by uncontrollable eating and resulting weight gain. The causes of binge-eating disorder are unknown. But family hist......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs